Geron Corp
Most Recent
Geron: One of the Best-Performing Biotech Stocks in Past Month
Geron (GERN) has been one of the best-performing biotechnology companies in the last month, rising 67.1% since August 10.
Geron Stock Rose 32% in Week Ended August 24
On August 24, Geron (GERN) stock rose ~28.78% to $5.19 from its prior day’s close of $4.03.
Understanding Geron Corp’s IMerge Trial
IMerge, a two-part clinical trial, is evaluating Geron’s (GERN) imetelstat in transfusion-dependent patients with low- or intermediate-risk myelodysplastic syndromes who have relapsed after or are refractory to prior treatment with an erythropoiesis-stimulating agent.
A Look at Geron’s Imetelstat Research Program
IMbark, a Phase 2 clinical trial, is evaluating two dose levels of Geron’s (GERN) imetelstat in ~200 myelofibrosis patients who have relapsed after or are refractory to prior treatment with a janus kinase inhibitor.
Analyzing Geron’s Financial Performance
In Q1 2018, Geron’s (GERN) license fee and royalty revenue fell YoY (year-over-year) to $318,000 from $537,000, with license fee revenue falling YoY to $248,000 from $409,000.
Exploring Geron’s Financial Performance
In fiscal 2017, Geron (GERN) generated revenues of $1 million through license fees and royalties compared with $6.1 million in fiscal 2016.
A Close Look at Geron’s Imetelstat
Geron contributes 50% of the development costs for the imetelstat trials. Imetelstat was granted fast track designation by the FDA in October 2017.
XBI on a Downward Slope, but How Steep?
On March 16, pressure on biotech and healthcare continued, with the SPDR S&P Biotech ETF (XBI) losing another 1.2% that day and closing at $48.31.
Moving Averages of XBI’s Holdings Have Improved
The moving averages of the stocks in the SPDR S&P Biotech ETF (XBI) have seen drastic improvements recently.
How are IBB’s Subgroups Performing?
The iShares Nasdaq Biotechnology ETF (IBB) gives good exposure to various industries in the biotechnology industry. As of October 19, IBB rose by ~0.5%.
